EP0954311A1 - Utilisation du 1- 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux - Google Patents

Utilisation du 1- 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Info

Publication number
EP0954311A1
EP0954311A1 EP97902426A EP97902426A EP0954311A1 EP 0954311 A1 EP0954311 A1 EP 0954311A1 EP 97902426 A EP97902426 A EP 97902426A EP 97902426 A EP97902426 A EP 97902426A EP 0954311 A1 EP0954311 A1 EP 0954311A1
Authority
EP
European Patent Office
Prior art keywords
treatment
disorders
dementia
cerebral
trifluoromethylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97902426A
Other languages
German (de)
English (en)
French (fr)
Inventor
Tiziano Croci
Jacqueline Fournier
Umberto Guzzi
Costantino Palmieri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of EP0954311A1 publication Critical patent/EP0954311A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to the use of l- [4- (3-trifluoromethylphenyl) - 1,2,3,6-tetrahydropyrid-1-yl] -2- (6,7-dimethoxynapht-2-yl) ethane (I ) for the preparation of drugs intended for the treatment and / or prophylaxis of cerebral and neuronal diseases.
  • EP 0 458 696 describes the use of 1- [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine for the preparation of medicaments intended for the treatment of neurodegeneration.
  • the compound of formula (I) and its pharmaceutically acceptable salts have the capacity to increase the survival of neurons.
  • the present invention therefore relates to the use of l- [4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyrid-1-yl] -2- (6,7-dimethoxynapht-2-yl) ethane, of formula (I)
  • pharmaceutically acceptable salts of the compound of formula (I) mention may be made of those formed with pharmaceutically acceptable acids, for example, those with mineral acids, such as the hydrochloride, hydrobromide, borate, phosphate, sulphate, hydrogen sulfate, hydrogen phosphate and those with organic acids, such as citrate, benzoate, ascorbate, methyl sulfate, naphthalene-2-sulfonate, picrate, fumarate, maleate, malonate, oxalate, the succinate, acetate, tartrate, mesylate, tosylate, isethionate, ⁇ -ketoglutarate, ⁇ -glycerophosphate, glucose-1-phosphate.
  • mineral acids such as the hydrochloride, hydrobromide, borate, phosphate, sulphate, hydrogen sulfate, hydrogen phosphate
  • organic acids such as citrate, benzoate, ascorbate, methyl sulfate, naphthal
  • the septal region was removed from embryos of 17-18 day old rats under a dissecting microscope under sterile conditions, then it was dissociated in a trypsin-ethylenediaminotetraacetic acid (EDTA) medium.
  • EDTA trypsin-ethylenediaminotetraacetic acid
  • neuroblasts are then seeded in the wells of a titration plate at the rate of 17x10 cells / cm ⁇ , in a non-serum culture medium consisting of
  • test compounds are dissolved in dimethylsulfoxide (DMSO) and diluted as required by the culture medium.
  • DMSO dimethylsulfoxide
  • the neuroblasts are kept in plates containing the test compound or the corresponding solvent for 4 days without changing the medium.
  • the medium is replaced by a tetrazolium salt dissolved in the culture medium (0.15 mg / ml).
  • the cells are then placed in an oven at 37 ° C for 4 hours.
  • the mitochondrial succinodehydrogenases of living cells reduce the tetrazolium salt to formazan blue, which, after dissolution in DMSO, measures the optical density at 540nm, a density which is linearly correlated with the number of living cells (Manthorpe et al., Dev. Brain Res ., 1988, 25: 191-198).
  • the compound of formula (I) as well as its pharmaceutically acceptable addition salts and its solvates can be used for the preparation of pharmaceutical compositions indicated in the treatment and / or prophylaxis of all diseases which involve neuronal degeneration. More particularly, the compounds of the invention can be used, alone or in co-administration or association with other active ingredients acting on the CNS, for example selective M1 cholinomimetics, antagonists
  • nootropics such as piracetam, in particular in the following indications: memory disorders, vascular dementia, post-encephalitic disorders, post-apoplectic disorders, post-traumatic syndromes due to a cranial trauma, disorders deriving from cerebral anoxia, Alzheimer's disease, senile dementia, subcortical dementia, such as Huntington's chorea and Parkinson's disease, dementia caused by AIDS, neuropathies derived from morbidity or damage to the sympathetic or sensory nerves, and brain diseases, such as edema cerebral, and the spinocerebellar degenerations, the degenerations of the motor neurons, like for example amiotrophic lateral sclerosis.
  • the administration of the compounds of the invention can be suitably carried out by oral, parenteral, sublingual or transdermal route.
  • the quantity of active principle to be administered in the treatment of cerebral and neuronal disorders according to the method of the present invention depends on the nature and the gravity of the affections to be treated as well as on the weight of the patients. Nevertheless, the preferred unit doses will generally comprise from 0.5 to 700 mg, advantageously from 2 to 300 mg, preferably from 5 to 150 mg, for example between 5 and 50 mg, namely 1, 2, 5, 10, 15 , 20, 25, 30, 40 or 50 mg of product.
  • unit doses will normally be administered one or more times a day, for example 2, 3, 4, or 5 times a day, preferably one to three times a day, the overall dose in humans being variable between 0.5 and 1400 mg per day, advantageously between 1 and 1000 mg per day, for example from 2 to 500 mg, more suitably from 5 to 200 mg per day.
  • the active principle can be administered in unit administration forms, either as it is, for example in lyophilized form, either in admixture with conventional pharmaceutical carriers, animals and humans for the treatment of the above conditions.
  • Suitable unit administration forms include oral forms such as optionally scored tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, administration forms under - cutaneous, intramuscular or intravenous, forms of local administration and forms of rectal administration.
  • the main active ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
  • a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
  • the tablets can be coated with sucrose or other suitable materials or they can be treated so that they have a prolonged or delayed activity and that they continuously release a predetermined quantity of active principle.
  • a preparation in capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard capsules.
  • a preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
  • a sweetener preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
  • Water dispersible powders or granules may contain the active ingredient in admixture with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or correctors taste.
  • Suppositories are used for rectal administration which are prepared with binders that melt at rectal temperature, for example cocoa butter or polyethylene glycols.
  • aqueous suspensions, saline solutions or sterile injectable solutions which contain pharmacologically compatible dispersing agents and / or wetting agents, for example propylene glycol or butylene glycol.
  • the active principle can also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
  • the active principle can also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters.

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP97902426A 1997-02-03 1997-02-03 Utilisation du 1- 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux Withdrawn EP0954311A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1997/000202 WO1998033502A1 (fr) 1997-02-03 1997-02-03 Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Publications (1)

Publication Number Publication Date
EP0954311A1 true EP0954311A1 (fr) 1999-11-10

Family

ID=9502506

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97902426A Withdrawn EP0954311A1 (fr) 1997-02-03 1997-02-03 Utilisation du 1- 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux

Country Status (11)

Country Link
EP (1) EP0954311A1 (cs)
JP (1) JP2001511141A (cs)
AU (1) AU1607397A (cs)
CA (1) CA2279326A1 (cs)
CZ (1) CZ275399A3 (cs)
EE (1) EE9900332A (cs)
HU (1) HUP0000767A3 (cs)
IL (1) IL130994A0 (cs)
IS (1) IS5117A (cs)
TR (1) TR199901722T2 (cs)
WO (1) WO1998033502A1 (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6272180B1 (en) * 1997-11-21 2001-08-07 Sharp Laboratories Of America, Inc. Compression and decompression of reference frames in a video decoder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9833502A1 *

Also Published As

Publication number Publication date
CZ275399A3 (cs) 1999-12-15
IL130994A0 (en) 2001-01-28
CA2279326A1 (fr) 1998-08-06
EE9900332A (et) 2000-02-15
AU1607397A (en) 1998-08-25
WO1998033502A1 (fr) 1998-08-06
TR199901722T2 (xx) 2000-08-21
HUP0000767A3 (en) 2000-10-30
IS5117A (is) 1999-07-15
JP2001511141A (ja) 2001-08-07
HUP0000767A2 (hu) 2000-09-28

Similar Documents

Publication Publication Date Title
EP0458696B1 (fr) Utilisation d'une 1-(2-naphtyléthyl)-4-(3-trifluorométhylphényl)-1,2,3,6-tétrahydropyridine pour la préparation de médicaments destinés au traitement de troubles cérébraux et neuronaux
EP0687176B1 (fr) Application du riluzole dans le traitement du neuro-sida
EP0369887B1 (fr) Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs
WO1999058117A1 (fr) Utilisation de composes reduisant l'apoptose
FR2501506A1 (fr) Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
EP1173179A2 (fr) Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles depressifs majeurs
EP0412901B1 (fr) Utilisation de trifluorométhyl-phényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles de la motricité intestinale
EP0954311A1 (fr) Utilisation du 1- 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
EP1030671A1 (fr) Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer
EP0950048B1 (fr) 1-phenylalkyl-1,2,3,6-tetrahydropyridines pour le traitement de la maladie d'alzheimer
EP1133296A1 (fr) Nouvelle application therapeutique de la nicergoline
CA2361988A1 (fr) Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
FR2659853A1 (fr) Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
EP0370902B1 (fr) Utilisation de dérivés du chromanne pour preparer un medicament utile pour le traitement des états dépressifs
EP0950049B1 (fr) Diphenylalkyl-tetrahydropyridines, procede pour leur preparation et composition pharmaceutique les contenant
EP0786988B1 (fr) Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
WO1999040911A1 (fr) Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
EP0489640B1 (fr) Utilisation de phényléthanolaminotétralines pour la préparation de médicaments antidépressifs et anti-stress
EP0950053B1 (fr) Nouveaux derives de benzoylalkyl-1,2,3,6-tetrahydropyridines
EP0966276A1 (fr) Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants
FR2702656A1 (fr) Utilisation de dérivés de la tétrahydropyridine pour la préparation de médicaments cardioprotecteurs.
EP1237552B1 (fr) Association de lumilysergol et riluzole pour la prevention et/ou le traitement de maladies motoneuronales
KR20000070704A (ko) 대뇌 및 신경원 질환 치료용 약제의 제조에 사용되는 1-[4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리드-1-일]-2-(6,7-디메톡시나프트-2-일)에탄의 용도
FR2771007A1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer
MXPA99006885A (es) Hoja de impresion por inyeccion de tinta.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 19990714;LV PAYMENT 19990714;SI PAYMENT 19990714

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010831

RTI1 Title (correction)

Free format text: USE OF 1- 4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRID-1YL -2-(6,7-DIMETHOXYNAPHT-2-YL) ETHANE FOR PREPARING MEDICINES FOR THE TREATMENT OF CEREBRAL AND NEURONAL DISORDERS